title: Endothelin Receptor A Antagonism and Fetal Growth in Endothelial Nitric Oxide Synthase Gene Knockout Maternal and Fetal Mice.
abstract: Fetal growth restriction (FGR) is commonly associated with perinatal morbidity and mortality. Nitric oxide (NO) deficiency increases endothelin-1 (ET-1) production, and this increased ET-1 may contribute to the pathophysiology of NO deficiency-induced FGR. Using an endothelial NO synthase knockout mouse model of FGR, we sought to determine (a) the relative importance of maternal versus conceptus (fetal and placental) NO deficiency and (b) the contribution of ET-1 to the pathogenesis of FGR in this model. Fetal growth restriction occurred both with NO-deficient conceptuses in the setting of maternal NO production and with maternal NO deficiency in the setting of NO-producing conceptuses. Placental ET-1 expression was increased in NO-deficient dams, ET receptor A (ETA) production increased in endothelial nitric oxide synthase(+/-) placentas, and antagonism of ETA prevented FGR. These results demonstrate that both maternal and conceptus NO deficiency can contribute to FGR and suggest a role for ETA antagonists as therapeutic agents in FGR.
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston, IL, USA.
authors.forename: Kehuan
authors.initials: K
authors.lastname: Luo
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston, IL, USA Department of Obstetrics and Gynecology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA lthaete@northshore.org.
authors.forename: Larry G
authors.initials: LG
authors.lastname: Thaete
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston, IL, USA Department of Obstetrics and Gynecology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
authors.forename: Mark G
authors.initials: MG
authors.lastname: Neerhof
mesh_terms: D000818:Animals; D065130:Endothelin A Receptor Antagonists / Q000008:administration & dosage*; D019332:Endothelin-1 / Q000378:metabolism*; D005260:Female; D047109:Fetal Development / Q000187:drug effects; D005317:Fetal Growth Retardation / Q000378:metabolism*; D020567:Fetal Weight / Q000187:drug effects; D008431:Maternal-Fetal Exchange; D051379:Mice; D018345:Mice, Knockout; D052250:Nitric Oxide Synthase Type III / Q000172:deficiency* / Q000235:genetics; D010920:Placenta / Q000187:drug effects / Q000502:physiology; D011247:Pregnancy; D011759:Pyrrolidines / Q000008:administration & dosage; D012333:RNA, Messenger / Q000378:metabolism; D044022:Receptor, Endothelin A / Q000378:metabolism*
chemical_list: C467892:ABT 546; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1; D011759:Pyrrolidines; D012333:RNA, Messenger; D044022:Receptor, Endothelin A; D052250:Nitric Oxide Synthase Type III
keywords: endothelin antagonism; fetal growth restriction; mouse; nitric oxide synthase gene knockout; pregnancy